- Home
- GILT vs TSHA Comparison
GILT vs TSHA Comparison
Compare GILT & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILT
- TSHA
- Stock Information
- Founded
- GILT 1987
- TSHA 2019
- Country
- GILT Israel
- TSHA United States
- Employees
- GILT N/A
- TSHA N/A
- Industry
- GILT Radio And Television Broadcasting And Communications Equipment
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- GILT Technology
- TSHA Health Care
- Exchange
- GILT Nasdaq
- TSHA Nasdaq
- Market Cap
- GILT 400.3M
- TSHA 356.7M
- IPO Year
- GILT 1993
- TSHA 2020
- Fundamental
- Price
- GILT $6.34
- TSHA $1.38
- Analyst Decision
- GILT Strong Buy
- TSHA Strong Buy
- Analyst Count
- GILT 2
- TSHA 8
- Target Price
- GILT $8.50
- TSHA $6.63
- AVG Volume (30 Days)
- GILT 341.0K
- TSHA 1.6M
- Earning Date
- GILT 05-07-2025
- TSHA 05-13-2025
- Dividend Yield
- GILT N/A
- TSHA N/A
- EPS Growth
- GILT 6.30
- TSHA N/A
- EPS
- GILT 0.44
- TSHA N/A
- Revenue
- GILT $305,448,000.00
- TSHA $8,333,000.00
- Revenue This Year
- GILT $45.38
- TSHA N/A
- Revenue Next Year
- GILT $11.84
- TSHA N/A
- P/E Ratio
- GILT $14.87
- TSHA N/A
- Revenue Growth
- GILT 14.79
- TSHA N/A
- 52 Week Low
- GILT $4.04
- TSHA $1.17
- 52 Week High
- GILT $8.05
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- GILT 36.83
- TSHA 34.93
- Support Level
- GILT $6.58
- TSHA $1.59
- Resistance Level
- GILT $6.85
- TSHA $1.87
- Average True Range (ATR)
- GILT 0.21
- TSHA 0.15
- MACD
- GILT -0.06
- TSHA -0.01
- Stochastic Oscillator
- GILT 12.00
- TSHA 24.36
About GILT Gilat Satellite Networks Ltd.
Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs) and Transceivers. The company's solutions support multiple applications with a full portfolio of products to address key applications including broadband access, cellular backhaul, enterprise, in-flight connectivity, maritime, trains, defense, and public safety.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.